Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
6 "Chemoradiotherapy"
Filter
Filter
Article category
Publication year
Case Reports
Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report
In-Jung Kim, Sung Hwan Yoo, Jung Il Lee, Kwan Sik Lee, Hyun Woong Lee, Jin Hong Lim
J Liver Cancer. 2022;22(1):84-90.   Published online March 22, 2022
DOI: https://doi.org/10.17998/jlc.2022.03.07
  • 3,247 Views
  • 74 Downloads
  • 2 Citations
AbstractAbstract PDF
There are various methods for treating advanced hepatocellular carcinoma with portal vein invasion, such as systemic chemotherapy, transarterial chemoembolization, transarterial radioembolization, and concurrent chemoradiotherapy. These methods have similar clinical efficacy but are designed with a palliative aim. Herein, we report a case that experienced complete remission through “associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)” after concurrent chemoradiotherapy and hepatic artery infusion chemotherapy. In this patient, concurrent chemoradiotherapy and hepatic artery infusion chemotherapy induced substantial tumor shrinkage, and hypertrophy of the nontumor liver was sufficiently induced by portal vein ligation (stage 1 surgery) followed by curative resection (stage 2 surgery). Using this approach, long-term survival with no evidence of recurrence was achieved at 16 months. Therefore, the optimal use of ALPPS requires sufficient consideration in cases of significant hepatocellular carcinoma shrinkage for curative purposes.

Citations

Citations to this article as recorded by  
  • Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study
    Jae-Sung Yoo, Ji Hoon Kim, Hee Sun Cho, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Suho Kim, Jung Suk Oh, Ho Jong Chun, Pil Soo Sung
    Abdominal Radiology.2024;[Epub]     CrossRef
  • Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus?
    Won Hyeok Choe
    Journal of Liver Cancer.2022; 22(1): 1.     CrossRef
Close layer
Advanced Stage Hepatocellular Carcinoma Successfully Treated with Liver-directed Concurrent Chemoradiotherapy and Sequential Transarterial Radio-embolization
Minho Noh, Beom Kyung Kim, Seung Up Kim
J Liver Cancer. 2021;21(1):97-103.   Published online March 31, 2021
DOI: https://doi.org/10.17998/jlc.21.1.97
  • 3,371 Views
  • 79 Downloads
AbstractAbstract PDF
Optimal treatment strategies for patients with advanced hepatocellular carcinoma (HCC) is yet to be determined. Herein, we present a case of advanced HCC with tumor invasion into the right anterior portal vein and right hepatic vein where complete response (CR) was achieved via a multidisciplinary approach. This patient had a 10.5 cm-sized HCC invading segment VI, without extrahepatic spread. Liver function was classified as Child-Pugh class A, and the performance status was good. Transarterial radio-embolization (TARE) was performed 6 weeks after the completion of liver-directed concurrent chemoradiotherapy, and CR was confirmed 3 months post-TARE. Adoptive cell therapies were performed as adjuvant therapy and CR was maintained for over 15 months, until the local recurrence of a 2 cm-sized HCC was found. Therefore, in selected cases with preserved liver function, combination therapies, including LRTs and systemic therapy, can be a useful therapeutic option for advanced HCC.
Close layer
Original Article
Postoperative Chemoradiotherapy for R1 Resected Intrahepatic Cholangiocarcinoma
Kim, Kyung Su , Kim, Hwi Young , Kim, Kyubo , Yi, Nam Joon , Suh, Kyung Suk , Chie, Eui Kyu
J Liver Cancer. 2018;18(2):115-120.   Published online September 30, 2018
DOI: https://doi.org/10.17998/jlc.18.2.115
  • 2,497 Views
  • 86 Downloads
  • 2 Citations
AbstractAbstract PDF
Background/Aims
To investigative the potential role of postoperative chemoradiotherapy (CCRT) after R1 resection of intrahepatic cholangiocarcinoma (IHCC).
Methods
Between January 2000 and December 2012, medical records of 18 patients who underwent curative surgery with R1 resection for IHCC were retrospectively reviewed.
Results
Median age was 68 years and 12 patients (66.7%) were male. Median tumor size was 5.0 cm (range, 2.2-11.0) and 12 patients (66.7%) had T3 or higher disease. Lymph nodes were involved in four patients (22.2%). Vascular invasion and perineural invasion were present in 10 (55.6%) and 12 patients (66.7%), respectively. Postoperative CCRT given with 5-fluorouracil or gemcitabine were delivered to 7 patients (38.9%). Median radiation dose was 50.4 Gy (range, 45-54). Univariate analysis showed that median loco-regional recurrence-free survival (LRRFS), progression-free survival (PFS) and overall survival (OS) were prolonged for patients treated with CCRT (median LRRFS; 5.6 months vs. not reached, P<0.001, median PFS; 5.6 vs. 8.3 months, P=0.047, median OS; 15.0 vs. 26.6 months, P=0.064).
Conclusions
Postoperative CCRT improved the loco-regional control and PFS in IHCC patients with R1 resection. Further study is warranted to validate the role of postoperative CCRT for these patients.

Citations

Citations to this article as recorded by  
  • Precision therapy for intrahepatic cholangiocarcinoma: A case report on adjuvant treatment in a recurrent patient after surgery and literature review
    Bao Ying, Tao Tang, Li-Xing Zhang, Jian-Wei Xiong, Kai-Feng Zhao, Jia-Wei Li, Guo Wu
    Oncology Letters.2023;[Epub]     CrossRef
  • Stereotactic radiotherapy for intrahepatic cholangiocarcinoma
    Aditya Borakati, Farid Froghi, Ricky H Bhogal, Vasileios K Mavroeidis
    World Journal of Gastrointestinal Oncology.2022; 14(8): 1478.     CrossRef
Close layer
Case Reports
A Case of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Treated by Hepatic Artery Injection Chemotherapy and Radiotherapy
Sang Jin Kim, Byoung Kuk Jang, Jae Seok Hwang
J Liver Cancer. 2017;17(2):158-162.   Published online September 30, 2017
DOI: https://doi.org/10.17998/jlc.17.2.158
  • 2,767 Views
  • 21 Downloads
  • 1 Citation
AbstractAbstract PDF
External beam radiotherapy, transarterial chemoembolization and sorafenib are currently standard treatments for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis. However, hepatic arterial infusion chemotherapy has been applied to advanced stage HCC with a view to improving the therapeutic effect. We experienced a case of advanced HCC with clinical complete response after hepatic artery infusion chemotherapy and radiation therapy and report that.

Citations

Citations to this article as recorded by  
  • A Case of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Treated by Hepatic Arterial Infusion Chemotherapy and Radiotherapy
    Jin Yong Lee, Jeong-Ju Yoo, Seong Joon Chun, Sun Hyun Bae, Jae Myeong Lee, Sang Gyune Kim, Young Seok Kim
    Journal of Liver Cancer.2020; 20(1): 78.     CrossRef
Close layer
A Case of Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis
Tae Young Yang, Suk Pyo Shin, Joo Ho Lee, Yun Bin Lee, Hana Park, Seong Gyu Hwang, Kyu Sung Rim
J Liver Cancer. 2015;15(1):52-56.   Published online March 31, 2015
DOI: https://doi.org/10.17998/jlc.15.1.52
  • 1,272 Views
  • 9 Downloads
AbstractAbstract PDF
Patients with advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) have an extremely poor prognosis. Although the Barcelona Clinic Liver Cancer guideline recommends sorafenib in advanced HCC with PVT, which has provided survival benefits of 2 or 3 months compared to the placebo group, many liver cancer centers in Asia still select multimodality approaches including transarterial chemoembolization, radiofrequency ablation, radiation therapy (RT) as well as systemic/intra-arterial chemotherapy. Recently advanced RT technologies have shown potential to improve survival without severe radiationrelated toxicity. For locally advanced HCC patients with PVT, concurrent chemoradiotherapy (CCRT) has been applied as a loco-regional treatment and provides potential cures. We herein report our recent experience of a patient accompanying large HCC with PVT who successfully undergone CCRT followed by hepatic arterial infusion chemotherapy.
Close layer
Two Cases of Acute Hepatic Decompensation after Concurrent Chemoradiotherapy in Patients with Advanced Hepatocellular Carcinoma
Myoung Hwan Kim, Sang Hoon Ahn, Yong Han Paik, Kwan Sik Lee, Chae Yoon Chon, Young Myoung Moon, Jinsil Seong, Kwang Hyub Han
Journal of the Korean Liver Cancer Study Group. 2005;5(1):52-56.   Published online June 30, 2005
  • 522 Views
  • 1 Download
AbstractAbstract PDF
Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis. Concurrent chemoradiation (CCRT) therapy achieved favorable results in advanced hepatocellular carcinoma with portal vein thrombosis and can be considered as a treatment option for the management of advanced hepatocellular carcinoma.2 But, exacerbation of liver function during concurrent chemoradiotherapy is a critical complication in patients with hepatitis B virus (HBV) related HCC. Reactivation of HBV replication is a well-known complication in cancer patients receiving chemotherapy. We report two cases with acute exacerbation of liver function. The one
result
ed in hepatic decompensation after CCRT probably due to HCC progression and/or chemoradiotherapy and the other is due to reactivation of HBV replication after CCRT, who recovered after lamivudine and corticosteroid therapy.
Close layer

JLC : Journal of Liver Cancer